Form 4: Ionis Pharma CBO Exercises Options, Sells Shares

Joseph Baroldi, EVP and Chief Business Officer of Ionis Pharmaceuticals, executed a series of stock option exercises and subsequent share sales under a pre-arranged trading plan.

Summary

• Joseph Baroldi, EVP, Chief Business Officer, exercised 32,800 non-qualified stock options at an exercise price of $31.8 per share on September 3, 2025.
• Concurrently, Mr. Baroldi sold a total of 32,800 shares of common stock in multiple transactions on September 3, 2025.
• The sales included 2,800 shares at a weighted average price of $62.0101 (with sales occurring in a range from $58.59 to $59.26 as per footnote 2) and 30,000 shares at a weighted average price of $59.0864 (with sales occurring in a range from $62.00 to $62.03 as per footnote 3).
• All reported sales were conducted under a Rule 10b5-1 trading plan adopted on May 2, 2025.
• Following these transactions, Mr. Baroldi directly beneficially owns 31,926 shares of common stock and indirectly owns 3,071 shares through his spouse.
• He also retains beneficial ownership of 53,900 non-qualified stock options.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as the executive is realizing significant gains from option exercises, reflecting value in the company's stock. However, the insider selling, even if planned, can introduce a slight neutral or cautious sentiment.

Positives

• The executive is monetizing vested stock options, indicating a personal financial gain from the company's stock performance.
• The sale prices ($62.0101 and $59.0864) are significantly higher than the exercise price ($31.8), reflecting a substantial profit for the executive.
• The transactions were executed under a Rule 10b5-1 trading plan, which suggests pre-planned activity rather than a reaction to immediate, non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence, although this is mitigated by the pre-planned nature.
• A significant number of shares (32,800) were sold, reducing the executive's direct common stock holdings.

Corporate Governance

Related Party Transactions

• Joseph Baroldi's spouse indirectly beneficially owns 3,071 shares of common stock.

Stakeholder Impact

• Shareholders may observe a reduction in direct insider ownership, but the pre-planned nature of the sales under a Rule 10b5-1 plan mitigates potential negative interpretations.
• Employees holding stock options may view the executive's successful monetization as a positive signal regarding the value of their own equity incentives.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Options, Executive Compensation, Joseph Baroldi, Rule 10b5-1 Plan, Biotechnology, Pharmaceuticals